- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03247712
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer
Neoadjuvant Immunoradiotherapy: Head & Neck Cancer (NIRT-HNC)
Study Overview
Status
Intervention / Treatment
Detailed Description
This clinical trial uses nivolumab and radiotherapy prior to definitive surgical resection of tumors in patients with Head and Neck Squamous Cell Carcinoma (OHNSCC) with the primary objective of determining the safety and feasibility of preoperative immunoradiotherapy. In addition, tumor tissue, microbiome samples, and peripheral blood will be obtained for exploratory immunologic end points including measurements of tumor infiltrating immune cell populations based on flow cytometry and immunohistochemistry as well as circulating immunological parameters. This is the first study to evaluate the safety and efficacy of neoadjuvant radiation + PD-1 blockade in patients with HNSCC.
Estimated duration of 20 weeks: neoadjuvant immunoradiotherapy +/- surgery, followed by 6 doses of nivolumab 480mg IV q4wks +/- risk-adapted adjuvant therapy, per standard of care.
Phase I safety lead-in study (n = 6) evaluating the safety of neoadjuvant immunoradiotherapy in HNSCC, followed by phase II efficacy study (n = 28, total) to assess rate of down-staging after neoadjuvant immunoradiotherapy using Simon's two-stage design (futility assessment at n = 12).
The phase 1 portion of this study will require 6 patients and is therefore expected to complete in 6 months. Although non-surgical patients are eligible to enroll, they will not be counted toward accrual for either the primary safety endpoint, (as by definition, unplanned delay of surgery cannot exist); nor the secondary efficacy endpoint, as potential for surgical staging is absent.
So long as 2 or fewer surgical delays are observed (primary safety endpoint), the phase 2 portion of study will proceed (secondary efficacy endpoint). Patients will be followed for disease free and overall survival at 5 years.
Eligible patients may be enrolled unless a rate of unplanned surgical delay attributed to immunoradiotherapy is found to exceed 33% after enrollment of the first 6 patients. We estimate 10 to 20 patients per year will be enrolled.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Portland Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with squamous cell carcinoma of the head and neck region, (including mucosal,cutaneous, or nodal) who are planned for surgical resection and in the opinion of the investigator are able to safely undergo neoadjuvant anti-PD-1 and radiation. In addition, the following are eligible (but will not contribute toward total accrual): non-surgical cases that are planned for palliative RT or that refuse or are unfit for definitive concurrent chemotherapy.
- HPV status as determined by p16 immunostain
- Cohort 3: HPV-positive patients only
- Cohort 4: HPV-negative patients only
- Age 18 years or above with ability to give informed consent, comply with the protocol, and sign a study-specific consent document. Patients with history of psychiatric illness must be judged by the investigator as able to understand the investigational nature and risks associated with the therapy.
- Eastern Cooperative Oncology Group (ECOG) performance status deemed suitable by investigator for study requirements.
Laboratory values (most recent), must be within 6 weeks of week 0 on study:
- WBC ≥ 2000/uL, ANC ≥ 1000/uL
- Hgb > 8g/dL (patients may be transfused to reach this level)
- Platelets > 50,000 cells/mm3
- Creatinine ≤ 3 x ULN
- AST/ALT ≤ 5 x ULN for subjects without liver metastasis; or ≤ 8 x ULN for subjects with liver metastasis, [per investigator brochure]
- Total bilirubin ≤ 3 x ULN, (except subjects with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL)
- Negative pregnancy test (bHCG urine or serum, women of childbearing potential only)
- Women of child-bearing potential (WOCBP) must agree to follow adequate contraceptive practices to avoid pregnancy for the duration of treatment with nivolumab plus 5 half-lives of nivolumab (75 days) plus 30 days (duration of ovulatory cycle) for a total of 105 days post-treatment completion.
- Males who are sexually active with WOCBP must agree to follow adequate contraceptive practices to avoid pregnancy for the duration of treatment with study drug (s) plus 5 half lives of the study drug (75 days) plus 90 days (duration of sperm turnover) for a total of 165 days post-treatment completion.
Exclusion Criteria:
- Any clinical factors such as bleeding, active infection, or psychiatric factors that in the judgment of the investigator would preclude safe participation and compliance with study procedures.
- HNSCC for which radiation is not indicated during normal treatment course.
- Need for chronic maintenance with oral steroids ≥20mg daily prednisone equivalent; inhaled, topical or non-absorbed steroids are acceptable.
- History of or current active autoimmune disease, [e.g. including but not limited to inflammatory bowel diseases [IBD], rheumatoid arthritis, autoimmune hepatitis, systemic sclerosis (scleroderma and variants), systemic lupus erythematosus, autoimmune vasculitis, autoimmune neuropathies (such as Guillain-Barre syndrome)], which in the judgment of the investigator poses an active and significant morbidity risk. Vitiligo and adequately controlled endocrine deficiencies such as hypothyroidism are not exclusionary. Patient and investigator may opt to accept risk of autoimmune disease flare, based on shared-decision making with consideration of risk/benefit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Cohort 1
Nivolumab administration (3 doses) and radiation (5 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
|
Surgical Resection of Tumor
Nivolumab 240mg IV q2wks or 480mg IV q4wks
Other Names:
8Gy x 5 (Mon-Fri) GTV+3mm
|
Experimental: Treatment Cohort 2
Nivolumab administration (3 doses) and radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
|
Surgical Resection of Tumor
Nivolumab 240mg IV q2wks or 480mg IV q4wks
Other Names:
8Gy x 3 (Monday, Wednesday, Friday) GTV+3mm
|
Experimental: Treatment Cohort 3
Radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
|
Surgical Resection of Tumor
Nivolumab 240mg IV q2wks or 480mg IV q4wks
Other Names:
8Gy x 3 (Monday, Wednesday, Friday) GTV+3mm
|
Experimental: Treatment Cohort 4
Nivolumab administration (3 doses) and radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
|
Surgical Resection of Tumor
Nivolumab 240mg IV q2wks or 480mg IV q4wks
Other Names:
8Gy x 3 (Monday, Wednesday, Friday) GTV+3mm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with an Unplanned Delay to Surgery [Safety and Tolerability of Neoadjuvant Treatment]
Time Frame: 6 weeks
|
Safety endpoint: Number of patients with an Unplanned Delay to Surgery defined as any change to scheduled surgery date considered to be at least possibly related to neoadjuvant treatment.
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with decrease in tumor size or number of lymph nodes involved [Efficacy of Neoadjuvant Treatment]
Time Frame: 6 weeks
|
Efficacy endpoint: Number of patients with decrease in tumor size of greater than 10% or decrease in the number of lymph nodes involved by 10% by week 6.
|
6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Rom Leidner, MD, Providence Health and Services
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Carcinoma, Squamous Cell
- Head and Neck Neoplasms
- Squamous Cell Carcinoma of Head and Neck
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
Other Study ID Numbers
- NIRT-HNC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Centre Oscar LambretUnknownEpidermoid Head and Neck CancerFrance
-
Radboud University Medical CenterUnknown
Clinical Trials on Surgical Resection
-
Qazvin University Of Medical SciencesUnknownOral Lichen PlanusIran, Islamic Republic of
-
Zagazig UniversityCompleted
-
Fondazione Policlinico Universitario Agostino Gemelli...Technische Universität Dresden; University of Debrecen; Koc University Hospital; Hospital de la Santa creu i Sant Pau - Barcelona and other collaboratorsNot yet recruiting
-
Fudan UniversityShanghai Pulmonary Hospital, Shanghai, China; Zhoupu Hospital, Pudong New Area... and other collaboratorsRecruitingLung Adenocarcinoma | Surgical Procedure, Unspecified | PathologyChina
-
Grupo Espanol de Trabajo en Enfermedad de Crohn...Recruiting
-
University Hospital, ToursRecruiting
-
Toronto Sunnybrook Regional Cancer CentreOntario Clinical Oncology Group (OCOG); Ontario Cancer Research NetworkCompletedNon-Small Cell Lung CancerCanada
-
Fudan UniversityRecruitingLung Adenocarcinoma | Surgical Procedure, Unspecified | PathologyChina
-
Sahlgrenska University Hospital, SwedenCompleted
-
Alexandria UniversityCompletedGastrointestinal Stromal Tumor of DuodenumEgypt